Targeting folate receptor alpha for cancer treatment.
Loading...
Embargo End Date
ICR Authors
Authors
Cheung, A
Bax, HJ
Josephs, DH
Ilieva, KM
Pellizzari, G
Opzoomer, J
Bloomfield, J
Fittall, M
Grigoriadis, A
Figini, M
Canevari, S
Spicer, JF
Tutt, AN
Karagiannis, SN
Bax, HJ
Josephs, DH
Ilieva, KM
Pellizzari, G
Opzoomer, J
Bloomfield, J
Fittall, M
Grigoriadis, A
Figini, M
Canevari, S
Spicer, JF
Tutt, AN
Karagiannis, SN
Document Type
Journal Article
Date
2016-08-09
Date Accepted
2016-05-19
Abstract
Promising targeted treatments and immunotherapy strategies in oncology and advancements in our understanding of molecular pathways that underpin cancer development have reignited interest in the tumor-associated antigen Folate Receptor alpha (FRα). FRα is a glycosylphosphatidylinositol (GPI)-anchored membrane protein. Its overexpression in tumors such as ovarian, breast and lung cancers, low and restricted distribution in normal tissues, alongside emerging insights into tumor-promoting functions and association of expression with patient prognosis, together render FRα an attractive therapeutic target. In this review, we summarize the role of FRα in cancer development, we consider FRα as a potential diagnostic and prognostic tool, and we discuss different targeted treatment approaches with a specific focus on monoclonal antibodies. Renewed attention to FRα may point to novel individualized treatment approaches to improve the clinical management of patient groups that do not adequately benefit from current conventional therapies.
Citation
Oncotarget, 2016, 7 (32), pp. 52553 - 52574
Source Title
Publisher
IMPACT JOURNALS LLC
ISSN
1949-2553
eISSN
1949-2553